关于在丹麦治疗妊娠糖尿病的新指南的影响
Nina Lund Larsen1,2, Line Barner Dalgaard3, Lene Ring Madsen3,4,5
1Department of Gynaecology and Obstetrics, Gødstrup Hospital.
Danish medical journal
|November 28, 2025
概括
更新的丹麦妊娠糖尿病指南增加了胰岛素的使用,但没有改变最大剂量. 虽然劳动诱导率上升,但关键的胎儿和母亲结果保持稳定,这表明指南的有效性.
科学领域:
- 产科和妇科 产科和妇科
- 内分泌学 在内分泌学.
- 公共卫生 公共卫生
背景情况:
- 丹麦关于妊娠糖尿病 (GDM) 治疗的国家指南于2023年底更新,以加强血糖控制和减轻胎儿/母亲并发症.
- 预计更新的GDM指南将增加孕妇使用胰岛素治疗的比例.
- 本研究评估了新的GDM指南对胰岛素使用和产科结果的影响.
研究的目的:
- 评估胰岛素利用模式,以执行修订后的丹麦国家GDM治疗指南.
- 根据新的指导方针,评估GDM妇女的关键产科和产周结局.
- 为了比较胰岛素使用和指导方针实施前后期间的结果.
主要方法:
- 采用了回顾性队列研究设计,分析了来自Gødstrup医院的数据.
- 两组被比较:67名妇女在2024年5月至10月期间被诊断患有GDM (指南后) 和46名妇女在2023年三个月期间被诊断患有GDM (指南前).
- 收集的数据包括母亲人口统计,怀孕前的BMI,种族,教育,OGTT 2小时值,胰岛素治疗,分娩诱导和胎儿特征.
主要成果:
- 针对GDM的胰岛素治疗率显著增加,从2023年的26%增加到2024年的58% (p < 0.01).
- 每公斤最大胰岛素剂量在两段时间之间没有显著变化 (0.42 IU/kg/天).
- 劳动诱导率大幅增加 (2024年增长63%,2023年增长39%,p < 0.01),但产科或围产不良并发症的相应增加没有. 出生体重和z-score仍然可以比较.
结论:
- 实施新的GDM指南导致胰岛素治疗的发病率增加,但没有改变所需的最大胰岛素剂量.
- 增加的胰岛素使用与更高的分娩诱导率相关,可能会增加产科工作量.
- 该研究没有发现对出生体重或妊娠年龄较大的婴儿的发生有不良影响,这表明该指南的安全性.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Pathophysiology of Diabetes
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Diabetes: Symptoms, Diagnosis, and Complications
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is based on...
Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...


